Coverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0–15 Months of Age — 9 Provinces, China, 2019–2021

WHAT IS ALREADY KNOWN ON THIS TOPIC? Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China. A lack of official statistics, coupled with an insufficient body of published literature, hinders the accurate depiction of the current situation. WHAT IS...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lijun, Zhang, Zhaonan, Zhang, Xixi, Xu, Changsha, Song, Yifan, Li, Li, Ye, Jiakai, Wang, Zhiguo, Liang, Hui, Zhang, Weiyan, Lin, Ling, Li, Ning, Zhang, Shujun, Ma, Qianli, Du, Wen, Jiao, Yongzhuo, Cao, Lingsheng, Qi, Qi, Cao, Lei, Yu, Wenzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184383/
https://www.ncbi.nlm.nih.gov/pubmed/37197448
http://dx.doi.org/10.46234/ccdcw2023.072
Descripción
Sumario:WHAT IS ALREADY KNOWN ON THIS TOPIC? Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China. A lack of official statistics, coupled with an insufficient body of published literature, hinders the accurate depiction of the current situation. WHAT IS ADDED BY THIS REPORT? This study investigated the utilization of PCV13 and estimated its coverage in nine provinces across eastern, central, and western China between 2019 and 2021. Despite an annual increase in PCV13 usage during this period, the overall coverage remained suboptimal. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? Consideration should be given to incorporating vaccines into the Expanded Program of Immunization, reducing vaccine prices, and addressing the vaccination coverage gap between eastern and western regions when there is an adequate supply of PCV13, particularly with domestic vaccines.